First-in-class anaemia therapy granted expanded approval
The expanded authorisation of Reblozyl is based on a Phase…
The expanded authorisation of Reblozyl is based on a Phase III trial which showed that the treatment nearly doubled the percentage of certain transfusion-dependent anaemia patients achieving haemoglobin increase, compared to epoetin alfa.